Evaluating holistic needs assessment in outpatient cancer care--a randomised controlled trial: the study protocol by Snowden, wAustyn et al.
Evaluating holistic needs assessment in
outpatient cancer care—a randomised
controlled trial: the study protocol
Austyn Snowden,1 Jenny Young,2 Craig White,3 Esther Murray,4 Claude Richard,5
Marie-Therese Lussier,5 Ewan MacArthur,6 Dawn Storey,7 Stefano Schipani,8
Duncan Wheatley,9 Jeremy McMahon,10 Elaine Ross10
To cite: Snowden A,




controlled trial: the study
protocol. BMJ Open 2015;5:
e006840. doi:10.1136/
bmjopen-2014-006840
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006840).
Received 6 October 2014
Revised 10 March 2015
Accepted 10 April 2015






Introduction: People living with and beyond cancer
are vulnerable to a number of physical, functional and
psychological issues. Undertaking a holistic needs
assessment (HNA) is one way to support a structured
discussion of patients’ needs within a clinical
consultation. However, there is little evidence on how
HNA impacts on the dynamics of the clinical
consultation. This study aims to establish (1) how HNA
affects the type of conversation that goes on during a
clinical consultation and (2) how these putative
changes impact on shared decision-making and
self-efficacy.
Methods and analysis: The study is hosted by
10 outpatient oncology clinics in the West of Scotland
and South West England. Participants are patients
with a diagnosis of head and neck, breast, urological,
gynaecological and colorectal cancer who have
received treatment for their cancer. Patients are
randomised to an intervention or control group.
The control group entails standard care—routine
consultation between the patient and clinician. In the
intervention group, the patient completes a holistic
needs assessment prior to consultation. The
completed assessment is then given to the clinician
where it informs a discussion based on the patient’s
needs and concerns as identified by them. The
primary outcome measure is patient participation, as
determined by dialogue ratio (DR) and preponderance
of initiative (PI) within the consultation. The
secondary outcome measures are shared decision-
making and self-efficacy. It is hypothesised that HNA
will be associated with greater patient participation
within the consultation, and that shared decision-
making and feelings of self-efficacy will increase as a
function of the intervention.
Ethics and dissemination: This study has been
given a favourable opinion by the West of Scotland
Research Ethics Committee and NHS Research &
Development. Study findings will be disseminated
through peer-reviewed publications and conference
attendance.




There is currently a concerted political,
ethical and philosophical push towards
improving patient experience and care in the
UK National Health Service.1 2 Government
initiatives such as ‘Better Cancer Care: An
Action Plan’,3 and policy guidelines such as
‘Improving supportive and palliative care for
adults with cancer’4 address the need to
improve satisfaction, reduce distress, offer
support and save money by facilitating self-
care. Improved collaboration between patient
and clinician is central to this agenda.5
However, it is not clear how collaboration is
optimised, who should be sharing what deci-
sions, or how this may or may not impact on
outcomes.6 Therefore, evidence grounded in
the systematic analysis of the process and
impact of collaboration is rare as well as
important.
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first ran-
domised controlled trial to examine the impact of
holistic needs assessment (HNA) on the dynamics
of conversation and any subsequent impact on
shared decision-making and self-efficacy.
▪ We are only collecting data from one consultation per
patient. However, it is recommended that HNA
should be administered across the patient pathway
(at diagnosis, pretreatment, and then post-treatment).
Therefore, we are unable to comment on the impact
of HNA on the patient–clinician dynamic over time.
▪ Applying a holistic approach to patient care has
many benefits, but only around 25% of cancer
survivors in the UK receive a HNA and care plan.
Gaining a greater insight into the delivery and
experience of HNA in the clinical environment
will support evidence-based implementation of
HNA in the UK and internationally.
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Communication in cancer care is a well-researched
ﬁeld. Effective communication between the health pro-
fessional and the patient is associated with improved psy-
chological functioning of the patient,7 8 adherence to
treatment and pain control,9 and higher quality of life
and satisfaction.10 By contrast, it has been suggested11
that poor communication may have a number of nega-
tive effects on the patient and the treatment process,
including the nature and quality of information trans-
mission, decision-making, and the psychosocial experi-
ence of the patient.
There are inherent methodological and philosophical
challenges attached to this line of enquiry. Most notably
the idea of ‘poor’ or ‘effective’ communication is subject-
ive, with factors such as patient behaviour, time, resources
and previous training all affecting clinician communica-
tion style.12 The aim of the current study is to understand
more about the factors that may impact on the quality of
communication within the clinical consultation.
The intervention in this study is holistic needs assess-
ment (HNA). HNA is a checklist completed by the patient
prior to consultation. It signposts issues of emotional, prac-
tical, ﬁnancial and clinical concern. The purpose of HNA
is to identify a patient’s individual needs in order to facili-
tate better collaboration.13 During consultation, the HNA
facilitates a dialogue that will have the patient’s concerns
at the centre. In conjunction with a subsequent care plan,
the process supports timely intervention based on a collab-
orative, person-centred discussion.13
In order to gather pertinent data, we are going to audio
record clinical consultations. We recognise that this action
may have an impact in itself, potentially changing the
subtle dynamics of the consultation we intend to study.
Nevertheless, this is the same for both arms of the study
and a valuable method of analysis.14 Through detailed
examination of communication patterns within the con-
sultation, we intend to ascertain if and how a structured
conversation derived from personally identiﬁed patient
needs impacts on subsequent outcomes. To the best of our
knowledge this is the ﬁrst randomised controlled trial to
examine the impact of HNA on patient–clinician commu-
nication, and the subsequent impact on shared decision-
making and patient-reported self-efﬁcacy.
OBJECTIVES
The objectives are to examine
▸ The impact of HNA on consultation style;
▸ The impact of HNA on shared decision-making;
▸ The impact of HNA on patient-reported self-efﬁcacy.
In order to meet these objectives, the study will test the
following hypotheses:
▸ Use of HNA within clinical consultation will facilitate
increased levels of patient participation.
▸ Use of HNA within clinical consultation will facilitate
increased levels of shared decision-making.
▸ Use of HNA within clinical consultation will facilitate
increased feelings of self-efﬁcacy.
METHOD
Study design and setting
This protocol follows SPIRIT15 2013 guidelines.
It is a randomised controlled trial. The randomisation
pertains to the patients within each clinic. Data collec-
tion will occur within a post-treatment, outpatient
cancer clinic. Ten clinics from the West of Scotland and
South West England will participate. The clinics care for
patients with head and neck, breast, urological, gynaeco-
logical and colorectal cancer.
Prior to consultation, the patient will complete a
demographic questionnaire. Those in the intervention
group will then complete a holistic needs assessment
titled the ‘Concerns Checklist’ (ﬁgure 1). Within the
control group there will be no additional intervention,
care will continue as normal. Within both groups, the
consultation will be audio recorded.
Post-consultation, the patient will complete two sec-
ondary outcome measures; CollaboRATE5 and The
Lorig Self-efﬁcacy scale.16 CollaboRATE measures
patient perception of shared decision-making. One of
the strengths of CollaboRATE is the ability to complete
it in less than 30 s. The Lorig self-efﬁcacy scale is the
optimal measure for self-reported self-efﬁcacy in chronic
disease management according to Davies.17
Analysis of the audio recordings will be conducted by
MEDICODE.18 The MEDICODE system ascertains the
type of participation occurring within the consultation
according to two main measures: dialogue ratio (DR)
and preponderance of initiative (PI). DR is assessed by
coding how much of the consultation is discussion and
how much is instruction. PI is assessed by recording
which participant initiates aspects of conversation within
the consultation. These two measures (DR and PI)
together give a summary score of who is talking, what
about, and for how long. These measures can then be
analysed alongside the secondary outcome measures.
Eligibility criteria
The study sample will be composed of patients over the
age of 18. Eligible patients have undergone treatment for
their diagnosis and are attending a post-treatment clinic.
Exclusion criteria includes those deemed incapable of
consenting to participate as deﬁned by the Adults with
Incapacity (Scotland) Act (2000), and any reason which
in the opinion of the clinician/investigator interferes
with the ability of the patient to participate in the study. A
sample of 156 patients will be recruited. The clinicians
who deliver and assist with the clinics (n=16) span four
professional groups: consultant oncologist, cancer nurse
specialist, radiographer and surgeon.
Intervention
All participating clinicians will attend a training session
in the use of HNA to enhance standardisation and con-
cordance with the protocol. The training will be deliv-
ered by the study consultant psychologist (EM) and will
last for 2 h. It will involve a variety of teaching methods
2 Snowden A, et al. BMJ Open 2015;5:e006840. doi:10.1136/bmjopen-2014-006840
Open Access
group.bmj.com on August 13, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Figure 1 The concerns checklist.
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including presentation slides, interactive exercises and
ﬁnishes with a DVD that provides an example of a
patient and clinician using the HNA together. There will
also be an opportunity for the clinicians to complete the
HNA themselves. The aim is to equip the clinicians with
the skills and conﬁdence to respond to the patient’s
needs and concerns as identiﬁed through the assess-
ment. These responses may range from simply listening
to the patient to referring the patient to a member of
the wider team, such as a clinical psychologist, a chap-
lain, for ﬁnancial advice or social work.
Individuals in the intervention group will be given the
HNA (Concerns Checklist: ﬁgure 1) to complete before
consultation. Each clinic has identiﬁed a quiet area
where the researcher can sit with the patient, talk
through the form and then leave them to complete it.
They will be asked to hand it to their clinician when
they enter the consultation room. Any actions taken by
the patient or clinician will be recorded in a care plan.
A copy of the care plan will stay in patient notes, the
patient will keep a copy and a copy will be sent to any
other members of the multidisciplinary team who are
involved in the patient’s care.
If at any point during this process the patient decides
to withdraw, they will be free to do so without question.
All patients will be informed that withdrawing from the
study will not impact the care they receive in any way.
Outcomes
▸ Sociodemographic data: sex, age, postcode, ethnicity,
relationship status and education.
▸ Clinical data: cancer type and stage and form of treat-
ment received.
▸ Clinician data: gender, profession and years of
experience.
Data will also be obtained on who is present in the con-
sultation room. For example, the patient may bring a
family member with them.
This will allow the research team to examine what, if any
impact variables such as sex, age, ethnicity, support
network, and education have on the research aims.
Previous literature corroborates the inﬂuence of these
variables on distress within patients with cancer.19–21
Primary outcome measure
The primary outcome measure is patient participation
as measured by DR and PI using the conversational
coding software ‘MEDICODE’.22 PI measures the extent
to which conversations are started by the clinician or the
patient. The whole consultation is then summarised by
this measure according to who begins most of the con-
versation. It generates an overall score of −1 (all clin-
ician) to +1 (all patient). DR measures the extent to
which the whole consultation consists of monologues,
dyads and discussions. It generates an overall score of 0
(monologue) to 1 (dialogue). The output is a graphical
representation of these two summary measures.
MEDICODE was constructed to measure conversations
about medicine management23 and has not been used
previously to analyse cancer consultations. However, the
principles of DR and PI are transferable to any clinical
consultation, and were chosen for this study as the best
way of capturing the subtle shifts in conversation
hypothesised to occur.
Secondary outcome measures
1. Shared decision-making as measured by the
CollaboRATE scale5
CollaboRATE is a survey-based validated tool24 designed
to create a fast way to measure how much effort clini-
cians make to explain their patients’ health issues; how
much effort they make to listen to the issues that matter
most to their patients, and how much effort they make
to integrate the patients’ views and health beliefs.
2. Self-efﬁcacy as measured by the Lorig self-efﬁcacy
scale
The Lorig Self-Efﬁcacy for Managing Chronic Disease
6-Item Scale post-consultation encompasses several
domains common to many chronic diseases including
symptom control, role function, emotional functioning
and communicating with physicians. The scale has good
internal consistency and construct validity.17 25 It is free
and easy to use, and it has been extensively used at both
clinical and research levels within this patient popula-
tion.26 27 We acknowledge that a limitation of the tool is
that it has not been widely used with all cancer types.
However, it appears to be the best generic tool for this
purpose.17
Sample size calculation
To achieve statistical signiﬁcance, 78 patients are needed
in the experimental and 78 in the control groups. The
power calculation was done on G*Power 3.28 It is based
on the following assumptions.
The standard setting of α was adjusted from 0.05 to
0.0125 to account for the four primary end points (DR,
PI, CollaboRATE and Lorig).29 Power of 0.8 was
assumed as sufﬁcient to claim a difference between
groups as a consequence of the intervention. The antici-
pated effect size of d=0.5 is an estimate. There are no
data on the speciﬁc effects of the holistic needs assess-
ment technique proposed here. The value of d=0.5 was
arrived at by aggregating the reported effect sizes of
other comparable psychological interventions targeted
at improving psychological well-being in the cancer
population.30 31 Reported effect sizes range from negli-
gible (d=0.33 in older meta-analyses of interventions to
reduce anxiety in patients with cancer) to large effects
(d=0.77) claimed in some recent trials.31 Sheard and
McGuire also noted that the higher quality trials tended
to produce much higher effect sizes than those of lower
quality (0.63 vs 0.24). Given that this study proposal
meets their quality criteria for a high-quality trial (rando-
mised and >40 sample size), 0.5 can be considered a
coherent and conservative effect size estimate.
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Recruitment
While we plan to standardise recruitment as far as pos-
sible by selecting patients at the same point in their
treatment journey, we need to account for the different
pathways operating in the clinics. To this end, there are
two recruitment strategies.
▸ Following treatment, the patient will spend time in
hospital. A member of the clinical care team will
approach the patient and introduce the study. If the
patient expresses an initial interest the clinician will
give the patient a study pack. This will contain a
welcome letter, a participant information sheet and a
consent form.
OR
▸ During treatment, the patient will attend the clinic.
The clinician will introduce the study to the patient
at one of their scheduled appointments and hand
over a study pack.
Contact with patients will be done in person where
possible. However, in exceptional circumstances, if the
clinician has not made personal contact with the
patient, the hospital will write to the patient on behalf
of the research team and invite them to participate. The
letter will be sent in a plain envelope to protect the
patient’s privacy.
Randomisation
Blocked randomisation will be carried out by the
research team, using a computer-generated sequence to
ensure an almost equal number of patients within each
group. Stratiﬁed randomisation will be used to ensure
that patient groups are similar with respect to prognostic
factors such as age and sex. Patients will provide written
informed consent to participate before they are
informed as to which group (intervention or control)
they will be in. This is to avoid potential bias from
patients who may request to be in a certain group. The
randomisation sequence will be managed by the
research assistant using sealed envelopes. The coders
who analyse the audio recordings will be blind to the
allocation of patients to the intervention or control
group.
Data collection, management and analysis
There will be a 2-week pilot. This is to test the study proto-
col in practice and enable the construction of an optimal
coding framework for MEDICODE. It is our intention to
structure the coding framework around the theory of hol-
istic needs assessment, coding elements of the clinical
conversation according to the concern discussed:
Physical, Practical, Family/relationship, Emotional,
Spiritual and Lifestyle (see ﬁgure 1). This period will
allow for the testing of such a coding framework.
Changes to the protocol and coding framework will be
made accordingly.
The pilot will also allow time for broader reﬂection. The
research team will ask the clinicians to review their train-
ing, the patients’ response to the HNA, time and ease to
complete the HNA, and how their service is managing any
referrals. If the pilot uncovers any deﬁciencies in the
design this can be reviewed with the team and addressed.
Following this phase, the process is as follows. The
researcher will meet the patient in the waiting area of
the clinic. The researcher will summarise the study
process again, ensure the patient is happy to continue,
collect their consent form, and then ask them to com-
plete a demographic questionnaire. While the patient is
completing their demographic form, the researcher will
randomise the participant into an intervention or
control group. Individuals in the intervention group will
be given the HNA (Concerns Checklist ﬁgure 1) to com-
plete. At this stage, the patient will also have the oppor-
tunity to add their contact details should they wish to
take part in future follow-up interviews to discuss their
experiences of HNA (or not) and subsequent use of
support services.
When the patient is called, the researcher will accom-
pany them to the consultation room and start the record-
ing device. The researcher will then leave the consultation
room. The clinician will stop the recording device at the
end of the consultation. All patients (in both groups) will
return to the researcher, post-consultation, and complete
the Lorig self-efﬁcacy scale and CollaboRATE (ﬁgure 2).
Data collection will run for 12 months.
Data management
Research data and patient-related information will be
managed in accordance with relevant regulatory approvals.
Data analysis
The following statistical methods will be used for analys-
ing the data.
▸ Use of HNA within clinical consultation will facilitate
increased levels of patient participation
Patient participation within the consultation will be
measured by the two MEDICODE measures: PI and DR.
The data will ﬁrst be tested for outliers using box plots,
and for normality using a combination of PP, QQ plots
and Shapiro-Wilk test. If normality is found, homogen-
eity of variance between groups will be tested with
Levene’s test. Subsequent calculations will be based on
the outcomes of these assumption tests. If normality and
homogeneity of variance are established, mean PI and
DR will be compared between the intervention and
control group using a t test. If normality and/or homo-
geneity of variance cannot be established, a correspond-
ing non-parametric method will be employed.
▸ Use of HNA within clinical consultation will facilitate
increased levels of shared decision-making
Shared decision-making will be measured with
CollaboRATE. As shown above, the data will be tested for
outliers, normality and homogeneity of variance. If nor-
mality and homogeneity of variance are established,
mean collaboRATE scores will be compared between the
intervention and control groups using a t test; if not, a
corresponding non-parametric method will be employed.
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▸ Use of HNA within clinical consultation will facilitate
increased feelings of self-efﬁcacy
Self-efﬁcacy will be measured with the Lorig self-
efﬁcacy scale. As shown above, the data will be tested for
outliers, normality and homogeneity of variance. If nor-
mality and homogeneity of variance are established,
mean Lorig scores will be compared between the
intervention and control groups using a t test; if not, a
corresponding non-parametric method will be employed.
Methods for any additional analyses
Additionally, exploratory analyses will be carried out on
various associations. For example, associations will be
tested between the outcome variables and demographic
Figure 2 The study flow.
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data. We will also test for any potential associations
between DR and/or PI with CollaboRATE and Lorig
self-efﬁcacy across the whole sample. The purpose of
this is to ascertain any potential relationships between
these measures regardless of study group. For example,
it seems intuitive that people who are demonstrably
more involved in their consultations as evidenced by
high patient PI and DR scores would be more likely to
score highly for self-efﬁcacy and collaboration regardless
of study group.
We also plan to conduct subgroup analyses according
to characteristics of the clinicians. For example, we have
information on gender, profession and years of experi-
ence. These can be used to explore any potential trends
in greater depth.
It is acknowledged that a disadvantage of randomising
by patient is that the clinician will carry out consultations
with patients who are in the intervention and control
groups. Therefore, ‘learning’ from the consultations
where an HNA is applied may cross over into their inter-
actions with the control group. This would not impact
on clinician ability to identify needs personal to the
patient as the patient would not have thought about this
in the same manner as those completing an HNA.
Nevertheless, this ‘learning’ could potentially contamin-
ate the effect on communication between the groups.
However, since the time when HNA will be introduced
into their consultations is known, we can use this infor-
mation to investigate whether there is a trend in commu-
nication efﬁcacy through time. Fitting a trend line to the
full data set can do this. ‘Time’ can then be used as a
covariate in the analysis to remove any confounding
effect of ‘learning’.
Missing data
Cases will be excluded list-wise by default.32
DISCUSSION
Applying a holistic approach to patient care has many
beneﬁts.13 33 Yet, only around 25% of cancer survivors in
the UK receive a holistic needs assessment and care
plan.13 We therefore wish to gain a greater insight into
the delivery and experience of HNA in the clinical envir-
onment. The aim is to support evidence-based imple-
mentation of HNA in the UK.
The role of communication on patient outcome has
received considerable attention in the ﬁeld of cancer
care. Nevertheless, to the best of our knowledge, there
are no published randomised controlled trials that focus
on the patterns of communication between the patient
and clinician when a holistic needs assessment is used or
not. This study has a unique focus on the relationship
between communication style, shared decision-making
and self-efﬁcacy. Traditionally, in the UK, medical con-
sultations are led by the clinician, but there is evidence
that collaboration can be facilitated by training the clini-
cians in person-centred care.34 What we do not know is
whether this can also be achieved by prioritising
patients’ needs through the use of HNA. Further, we do
not know whether this leads to improved feelings of self-
efﬁcacy and a sense of shared decision-making.
Perception of self-efﬁcacy is particularly important, as
it is a critical feature of chronic disease management
and can predict the success of self-management pro-
grammes among patients.35 36 Findings from this study
may pave the way for exploring the impact of HNA over
time. For example, longitudinal follow-up could ascer-
tain whether there is any association between self-
efﬁcacy, self-management and the patient’s subsequent
use of the health service.
There are limitations to the study. As discussed above,
there is a risk of crossover learning from the experimen-
tal to the control. We could have mitigated this using a
cluster-randomised trial design, but this was not an
option due to the increased number of participants
required. Further, while crossover learning is a risk, we
do not consider it will undermine the key objectives as
the main intervention is the concerns checklist, not the
skills of the clinician.
Guidance suggests that HNA should be delivered
across the patient pathway, not just at the post-treatment
stage. We selected the post-treatment stage only to
accommodate anticipated difﬁculties around ensuring
the patient sees the same clinician throughout. In prac-
tice, this is not always the case which would confound
our results in this randomised controlled trial. There
were also pragmatic reasons. Practically, the clinics felt
most able to support this study at the post-treatment
stage. This is because at this stage there would be no
need for any radical changes to clinical practice. This
was considered paramount, as should we ﬁnd any favour-
able results they are more likely to be transferable to
routine practice in future.
Ethics and dissemination plans
This study was given a favourable opinion by the West of
Scotland Research Ethics Committee (14/WS/0126) on
3 June 2014. NHS Research & Development approval
followed on 26 August 2014. This study was also
approved by the Clinical Trials Executive Committee
within the Beatson West of Scotland Cancer Centre on
13 June 2014.
Recruitment began in January 2015, and completion
will occur on reaching the necessary sample size within
each group. It is predicted to take 12 months to reach
completion. It is recognised that as the patient’s symp-
toms ﬂuctuate, so may their capacity to consent.
Consent will be assessed by the clinician on the day of
the study. Patients without capacity to consent will be
excluded from data collection.
The dissemination of the ﬁndings will be predominately
carried out through publications in peer-reviewed journals
and attendance at national and international conferences.
Additionally, this body of work will be promoted by the
funders of the study, Macmillan Cancer Support UK.
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